Preoperative Stomach Cancer Induction Chemotherapy and Radiation Therapy

Inclusion Criteria: * Patients with potentially resectable adenocarcinoma of the stomach with histologic proof. * EUS or MRI stage T3-4, any N, M0. * Adequate bone marrow (defined as peripheral absolute granulocyte count of \> 2,000/μL, and platelet count of\>100,000/μL), liver (bilirubin \< 1.5 mg/dl), and renal functions (creatinine \< 1.5 mg/dl). * Absence of peritoneal disease by laparoscopic staging; no positive cytology of pleural, or pericardial effusion. * No prior major surgery or radiotherapy to the stomach, or immunotherapy or chemotherapy for any reason. * Patients must have a life expectancy of at least 16 weeks. * Performance status of \< 2 (Zubrod scale). * No biopsy proof of lymph node metastases outside the study field. * No evidence of metastatic disease to distant organs. * No presence of concurrent or previous malignancies \< 5 years, other than noninvasive skin cancer. * No uncontrolled or severe cardiac disease, diabetes or hypertension. * Signed study-specific consent form prior to study entry. Exclusion Criteria: * Evidence of metastatic disease * Prior chemotherapy or radiotherapy * Patients with a past history of cancer * Patients with other significant underlying medical conditions that may be aggravated by the study treatment or are not controlled * Pregnant or lactating females or female patients of childbearing potential who have not been surgically sterilized or are without adequate contraceptive measures * Cardiac failure or Sever Pulmonary disease * Patients with impaired gastrointestinal absorption for whatever reason * Patients medically unfit for cisplatin or taxol chemotherapy